This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Roche (RHHBY) Gets FDA Approval for Cobas EFGR Mutation Test
by Zacks Equity Research
Roche's (RHHBY) cobas EGFR Mutation Test v2 gets FDA nod as a companion diagnostic test with IRESSA.
AbbVie Posts Positive Data on Elagolix for Uterine Fibroids
by Zacks Equity Research
AbbVie (ABBV) reports positive top-line results from a phase III extension trial on its investigational candidate Elagolix for treating uterine fibroids in women.
Exact Sciences Inks Cologuard Co-Promotion Deal With Pfizer
by Zacks Equity Research
Exact Sciences (EXAS) reaches a co-promotion agreement with Pfizer to commercialize its non-invasive screening test for colorectal cancer, Cologuard. The stock rallies following this news.
4 Biotech Stocks Investors Can Bet on Post Solid Q2 Earnings
by Ekta Bagri
The biotech sector is expected to do well in the second half of 2018. Here we list four top biotech companies, which investors can add to their portfolio.
Mallinckrodt's Stannsoporfin Gets Complete Response Letter
by Zacks Equity Research
Mallinckrodt's (MNK) pipeline candidate, Stannsoporfin gets a Complete Response Letter from the FDA.
Don't Worry About An Inverted Yield Curve...YET
by John Blank
The U.S. economy should remain out of recession until 2020.
Alnylam Completes Enrollment in Phase III Givosiran Study
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) completes enrollment in the phase III ENVISION study ahead of schedule of its pipeline candidate, givosiran.
Pacira (PCRX) Rides High on Robust Exparel Performance
by Zacks Equity Research
Pacira (PCRX) focuses on improving sales of its flagship product Exparel. The drug's label expansion programs also look encouraging.
Allergan Falls on FDA's Rejection of Uterine Fibroids Drug
by Zacks Equity Research
FDA rejects Allergan's (AGN) new drug application for Esmya for the treatment of abnormal uterine bleeding in women with uterine fibroids, citing safety issues.
Infinity Focuses on Developing IPI-549 for Solid Tumors
by Zacks Equity Research
Infinity Pharmaceuticals (INFI) aims at developing its pipeline candidate, IPI-549.
Japan Nods to AstraZeneca's Tagrisso for First-Line NSCLC
by Zacks Equity Research
AstraZeneca (AZN) receives approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the label expansion of Tagrisso.
Alexion's BLA for ALXN1210 Gets Priority Review From FDA
by Zacks Equity Research
The FDA grants priority review to Alexion's (ALXN) BLA for its C5 complement inhibitor ALXN1210 with respect to the treatment of patients with paroxysmal nocturnal hemoglobinuria.
China Biologic Products (CBPO) Looks Good: Stock Adds 8.7% in Session
by Zacks Equity Research
China Biologic Products (CBPO) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
The Zacks Analyst Blog Highlights: Amazon, Petroleo Brazileiro, Gilead Sciences and KLA-Tencor
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Petroleo Brazileiro, Gilead Sciences and KLA-Tencor
Bristol-Myers' Opdivo Gets FDA Nod for Small Cell Lung Cancer
by Zacks Equity Research
Bristol-Myers' (BMY) blockbuster immuno-oncology drug Opdivo gets the FDA approval for small cell lung cancer indication, which shall further expand the addressable patient population of the drug.
Novo Nordisk Buys Ziylo to Develop Glucose Responsive Insulin
by Zacks Equity Research
Novo Nordisk A/S (NVO) acquires Ziylo Ltd. to speed up the development of glucose responsive insulins in a deal that could exceed $800 million.
Time for Jackson Hole: Global Week Ahead
by John Blank
The world???s central bankers are going to be in Jackson Hole, Wyoming speaking to Jerome Powell and the rest of the Fed contingent. Mr. Powell himself will speak Friday morning.
Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (GILD) Outperforming Other Medical Stocks This Year?
Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (GILD) Outperforming Other Medical Stocks This Year?
Regeneron, Teva Announce Positive Data on Osteoarthritis Drug
by Zacks Equity Research
Regeneron (REGN) along with partner Teva announces positive top-line results from a late-stage candidate on fasinumab in patients with chronic pain from osteoarthritis of the knee or hip.
Zacks Value Trader Highlights: Sony, Carrizo Oil & Gas, Intel, United Rentals and Gilead
by Zacks Equity Research
Zacks Value Trader Highlights: Sony, Carrizo Oil & Gas, Intel, United Rentals and Gilead
Glaxo, J&J's Dual Drug HIV Regimen Succeeds in Phase III Study
by Zacks Equity Research
Glaxo (GSK) and Johnson and Johnson report positive top line results from a late-stage study of their injectable two-drug regimen for the treatment of HIV.
Inovio Pharmaceuticals Initiates Dosing in HIV Vaccine Study
by Zacks Equity Research
Inovio Pharmaceuticals (INO) doses the first patient in a phase I/II study, which will evaluate its HIV vaccine Pennvax-GP's ability to bring about remission of HIV.
Lessons from a Legendary Value Investor
by Tracey Ryniec
Value investors are rare. Find out what it takes to be one and how to find value stocks from one of the greats.
Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children
by Zacks Equity Research
Vertex's (VRTX) cystic fibrosis drug, Kalydeco gets FDA approval to treat children aged 12 months to two years